V. Moilanen

A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial

V. Anttila, L. Pusa, K. Sammalkorpi, 2008, Scandinavian journal of infectious diseases.

Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)

R. Nissinen, E. Soini, M. Heikkinen, 2019, Scandinavian journal of gastroenterology.

29 Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection

P. Arkkila, E. Mattila, R. Uusitalo-Seppälä, 2010 .

Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection.

V. Anttila, P. Mattila, P. Arkkila, 2012, Gastroenterology.

Refractory coeliac disease in a country with a high prevalence of clinically‐diagnosed coeliac disease

L. Virta, K. Kaukinen, K. Kurppa, 2014, Alimentary pharmacology & therapeutics.

High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab – a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)*

S. Herrala, J. Jokelainen, K. Salminen, 2018, Scandinavian journal of gastroenterology.

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice.

S. Herrala, J. Jokelainen, K. Salminen, 2019, Biologicals : journal of the International Association of Biological Standardization.

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort

R. Nissinen, E. Soini, M. Heikkinen, 2020, European journal of gastroenterology & hepatology.